TY - JOUR
T1 - Selected anticancer drugs in Phase I trials in the United States (1979--1980).
AU - Muggia, F. M.
AU - Penta, J. S.
AU - Catane, R.
AU - Jensen-Akula, M. S.
AU - Charles, L. M.
PY - 1981
Y1 - 1981
N2 - Phase I trials in 1979 include some drugs representing totally new structures, new schedules of old compounds undergoing reevaluation, and second generation compounds. The rational development of analogs based on structure-activity relationships and on overcoming pharmacologic or toxicologic problems of parent compounds requires much future emphasis; two such examples (pentamethylmelamine and AZQ) are cited here. For all drugs, a plan of clinical development should ensure a more thorough initial evaluation as well as validation of concepts and systems that have prompted their introduction into the clinic. Establishment of clinical usefulness for the new structures, and particularly for three compounds herein reintroduced after a long period of oblivion, would constitute tangible proof of methodological and technological advances that have taken place in the development and clinical evaluation of anticancer drugs.
AB - Phase I trials in 1979 include some drugs representing totally new structures, new schedules of old compounds undergoing reevaluation, and second generation compounds. The rational development of analogs based on structure-activity relationships and on overcoming pharmacologic or toxicologic problems of parent compounds requires much future emphasis; two such examples (pentamethylmelamine and AZQ) are cited here. For all drugs, a plan of clinical development should ensure a more thorough initial evaluation as well as validation of concepts and systems that have prompted their introduction into the clinic. Establishment of clinical usefulness for the new structures, and particularly for three compounds herein reintroduced after a long period of oblivion, would constitute tangible proof of methodological and technological advances that have taken place in the development and clinical evaluation of anticancer drugs.
UR - http://www.scopus.com/inward/record.url?scp=0019477356&partnerID=8YFLogxK
U2 - 10.1007/978-3-642-81565-2_16
DO - 10.1007/978-3-642-81565-2_16
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:0019477356
SN - 0080-0015
VL - 76
SP - 192
EP - 208
JO - Recent Results in Cancer Research
JF - Recent Results in Cancer Research
ER -